From Medicineworld.org: Marine Bacteria Compound For Multiple Myeloma
Cancer blog: I manage the cancer blog with lots of help and support form other bloggers. Through this cancer blog my friends and I try to bring stories of hope for patients with cancer. The cancer blog often republishes important blog posts from other cancer related blogs at Medicineworld.org. If you are searching for a blog that covers wide variety of cancer topics, this may be the one for you.
Breast cancer blog: Breast cancer blog is run by Emily and other bloggers and they bring you the latest stories, news and events that are related to breast cancer. Increasing awareness about breast cancer among women and in the general population is the main goal of this breast cancer blog.
Lung cancer blog: Lung cancer blog is managed by Scott with the help of other bloggers. Through this blog Scott and his friends constantly remind the readers about the dangers of smoking. It's a never-ending struggle against this miserable disease with which a social stigma of smoking is associated.
Colon cancer blog: Colon cancer blog is run by Sue and other bloggers. Sue brings a personal touch to the colon cancer blog since her mother died of colon cancer few years ago. She writes about stories, research news and advances in treatment related to colon cancer.
Prostate cancer blog: Prostate cancer is the most common cancer among American men. American Cancer Society estimates that over 230,000 new cases of prostate cancer occur in the United state every year. This important blog about prostate cancer is run by Mark and other bloggers. This blog brings news, stories, and other personal observations related to prostate cancer.
Medicineworld.org publishes a diabetes watch blog and this blog is run by JoAnn other bloggers. This diabetes watch blog brings you the latest in the field of diabetes. This includes personal stories, advances in diagnosis and treatment, and other observations about diabetes. Improving awareness about diabetes is an important mission of this group.
Marine Bacteria Compound For Multiple Myeloma
Dharminder Chauhan, PhDAn anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current therapys, report Dana-Farber Cancer Institute scientists in the recent issue of Cancer Cell.
The experimental compound, NPI-0052, has been found to block or inhibit cancer cells' proteasomes from working effectively. The proteasome work as a cell's "garbage disposal," chewing up and disposing of old, unwanted proteins. With their proteasome jammed, cells die from the backup of damaged proteins.
"Proteasome inhibition is a key therapeutic target and bortezomib (Velcade™) was the first in a new class of compounds in multiple myeloma. NPI-0052 is a novel proteasome inhibitor with a chemical structure and action that is distinct from bortezomib, and has the promise of being even more effective for patients," says Kenneth Anderson, MD, director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber, and senior author of the report.
The compound will be moved into Phase I clinical trials in early 2006, say officials of Nereus Pharmaceuticals in San Diego, the developer of NPI-0052. The compound will be tested as a single agent and subsequently in combination with other therapys.
Multiple myeloma is a currently incurable cancer of the bone marrow that causes a plunge in the production of vital red and white blood cells. Eventhough relatively rare, it is the second most common type of blood cancer and accounts for 11,000 deaths annually in the United States. Bortezomib, approved by the Food and Drug Administration in 2003 for relapsed myeloma patients and subsequently for patients who have received at least one previous therapy, demonstrated in clinical trials that it extended the time to disease progression and also improved survival.
Though less toxic than conventional chemotherapy, bortezomib does have significant side effects in some myeloma patients, including altered blood counts and nerve pain. In some patients, the disease can be resistant or become resistant to bortezomib.
Because NPI-0052 and bortezomib attack the same intracellular target in different ways, the Dana-Farber scientists contend that combining these two agents might be more effective than using either treatment alone - and be better tolerated by patients as well.
In preclinical studies, NPI-0052 blocks a wider range of proteasome activities than bortezomib, say the researchers, and works at lower doses. NPI-0052 also appears to be less toxic to normal cells. Bortezomib is currently given by intravenous infusion. "NPI-0052 can be given orally, eventhough the first clinical trials will be using the intravenous route," says Paul Richardson, MD, who is also a co-author in this study and will be leading the Phase-I clinical trial in myeloma at Dana-Farber.
NPI-0052 was discovered by William Fenical, PhD, and his collaborators at The Scripps Institute of Oceanography during the fermentation of Salinispora, a new class of marine gram-positive bacteria identified in sediment samples from the ocean floor. The substance has shown strong anticancer properties in laboratory tests. Nereus Pharmaceuticals holds an exclusive license to the compound for drug development.
Experiments with NPI-0052 began at Dana-Farber in 2003, said Dharminder Chauhan, PhD, lead author of the paper along with Laurence Catley, PhD. When added to cells from patients whose disease was resistant to both standard drugs and bortezomib, the compound efficiently killed the cells. Analyses showed that NPI-0052 and bortezomib express different profiles for inhibiting the three major proteasome activities.
In mice implanted with human myeloma tumor cells, NPI-0052 was well tolerated, prolonged survival and significantly reduced the rate of cancer recurrences. Because NPI-0052 and bortezomib block the proteasome in different ways, the scientists tested them together on myeloma cells. They found that the cancer cells were killed more effectively by the combination than either compound alone - without additional toxicity to normal cells.
"This is a laboratory advance that shows clinical promise," says Dr. Chauhan. "We think this is going to be the '2006 Model' of proteasome inhibitors."
Michael Palladino, Jr., PhD, chief technical officer of Nereus Pharmaceuticals, said that the company plans to file an investigational new drug (IND) application by the end of the year, with trials at several centers - including Dana-Farber - starting in early 2006.
Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.
Source: Dana-Farber Cancer Institute
Did you know?
An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current therapys, report Dana-Farber Cancer Institute scientists in the recent issue of Cancer Cell.
Medicineworld.org: Marine Bacteria Compound For Multiple Myeloma
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.